Unknown

Dataset Information

Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort.


ABSTRACT: Recombinant adeno-associated virus (rAAV) vectors are a promising platform for in vivo gene therapy. The presence of neutralizing antibodies (Nab) against AAV capsids decreases cell transduction efficiency and is a common exclusion criterion for participation in clinical trials. Novel engineered capsids are being generated to improve gene delivery to the target cells and facilitate success of clinical trials; however, the prevalence of antibodies against such capsids remains largely unknown. We therefore assessed the seroprevalence of antibodies against a novel synthetic liver-tropic capsid AAV-LK03. We measured seroprevalence of immunoglobulin (Ig)G (i.e., neutralizing and nonneutralizing) antibodies and Nab to AAV-LK03 in a cohort of 323 UK patients (including 260 pediatric) and 52 juven

SUBMITTER: Perocheau DP 

PROVIDER: S-EPMC6343184 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature